Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma

Cancers avoid immune surveillance through an array of mechanisms, including perturbation of HLA class I antigen presentation. Merkel cell carcinoma (MCC) is an aggressive, HLA-I–low, neuroendocrine carcinoma of the skin often caused by the Merkel cell polyomavirus (MCPyV). Through the characterization of 11 newly generated MCC patient-derived cell lines, we identified transcriptional suppression of several class I antigen presentation genes. To systematically identify regulators of HLA-I loss in MCC, we performed parallel, genome-scale, gain- and loss-of-function screens in a patient-derived MCPyV-positive cell line and identified MYCL and the non-canonical Polycomb repressive complex 1.1 (PRC1.1) as HLA-I repressors. We observed physical interaction of MYCL with the MCPyV small T viral antigen, supporting a mechanism of virally mediated HLA-I suppression. We further identify the PRC1.1 component USP7 as a pharmacologic target to restore HLA-I expression in MCC.

[1]  J. Decaprio,et al.  Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma , 2022, JCI insight.

[2]  Gartin Ashley K,et al.  Merkel cell carcinoma sensitivity to EZH2 inhibition is mediated by SIX1 derepression. , 2022, The Journal of investigative dermatology.

[3]  Eiryo Kawakami,et al.  Variant PCGF1-PRC1 links PRC2 recruitment with differentiation-associated transcriptional inactivation at target genes , 2021, Nature Communications.

[4]  Jennifer G. Abelin,et al.  Optimized Liquid and Gas Phase Fractionation Increases HLA-Peptidome Coverage for Primary Cell and Tissue Samples , 2021, Molecular & cellular proteomics : MCP.

[5]  Jesse H. Arbuckle,et al.  Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. , 2020, Immunity.

[6]  M. Washburn,et al.  Merkel cell polyomavirus activates LSD1-mediated blockade of non-canonical BAF to regulate transformation and tumorigenesis , 2020, Nature Cell Biology.

[7]  Sarah A. Boswell,et al.  Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism , 2020, Scientific Reports.

[8]  G. Sauter,et al.  Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms , 2020, Cellular Oncology.

[9]  Michael K. Slevin,et al.  ViroPanel: Hybrid capture and massively parallel sequencing for simultaneous detection and profiling of oncogenic virus infection and tumor genome. , 2020, The Journal of molecular diagnostics : JMD.

[10]  N. Hacohen,et al.  A large peptidome dataset improves HLA class I epitope prediction across most of the human population , 2019, Nature Biotechnology.

[11]  Kristian Cibulskis,et al.  Calling Somatic SNVs and Indels with Mutect2 , 2019, bioRxiv.

[12]  R. Tothill,et al.  An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer , 2019, Cancer cell.

[13]  J. Becker,et al.  Conversion of Sox2-dependent Merkel cell carcinoma to a differentiated neuron-like phenotype by T antigen inhibition , 2019, Proceedings of the National Academy of Sciences.

[14]  V. Sondak,et al.  The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy , 2019, Clinical Cancer Research.

[15]  Aviad Tsherniak,et al.  Extracting Biological Insights from the Project Achilles Genome-Scale CRISPR Screens in Cancer Cell Lines , 2019, bioRxiv.

[16]  R. Russell,et al.  EZHIP / CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma. , 2019, Neuro-oncology.

[17]  E. Vellenga,et al.  USP7 as part of non-canonical PRC1.1 is a druggable target in leukemia , 2019, bioRxiv.

[18]  Joshua M. Korn,et al.  Next-generation characterization of the Cancer Cell Line Encyclopedia , 2019, Nature.

[19]  J. Utikal,et al.  Characterization of six Merkel cell polyomavirus‐positive Merkel cell carcinoma cell lines: Integration pattern suggest that large T antigen truncating events occur before or during integration , 2019, International journal of cancer.

[20]  Michael K. Slevin,et al.  Clinical and molecular characterization of virus-positive and virus-negative Merkel cell carcinoma , 2019, bioRxiv.

[21]  Eilon Barnea,et al.  Pro-inflammatory Cytokines Alter the Immunopeptidome Landscape by Modulation of HLA-B Expression , 2019, Front. Immunol..

[22]  Koichi S. Kobayashi,et al.  Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance , 2019, Immunogenetics.

[23]  Jingwei Cheng,et al.  Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response , 2018, Proceedings of the National Academy of Sciences.

[24]  Alyssa R. Richman,et al.  Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial , 2018, Nature.

[25]  Yassen Assenov,et al.  Maftools: efficient and comprehensive analysis of somatic variants in cancer , 2018, Genome research.

[26]  W. J. Valente,et al.  Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA , 2018, Nature Communications.

[27]  L. Ni,et al.  Interferon gamma in cancer immunotherapy , 2018, Cancer medicine.

[28]  D. Jackson,et al.  MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma , 2018, Science Translational Medicine.

[29]  Ronald J. Moore,et al.  Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography–mass spectrometry , 2018, Nature Protocols.

[30]  M. Ghosh,et al.  Emerging insights into HAUSP (USP7) in physiology, cancer and other diseases , 2018, Signal Transduction and Targeted Therapy.

[31]  M. Oliveira,et al.  Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion , 2018, Front. Immunol..

[32]  J. Sage,et al.  Are there Multiple Cells of Origin of Merkel Cell Carcinoma? , 2017, Oncogene.

[33]  K. Takeda,et al.  The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion , 2017, International journal of molecular sciences.

[34]  James T. Elder,et al.  RNA-seq identifies a diminished differentiation gene signature in primary monolayer keratinocytes grown from lesional and uninvolved psoriatic skin , 2017, Scientific Reports.

[35]  R. Weiss,et al.  Transcriptome profiling identifies regulators of pathogenesis in collagen VI related muscular dystrophy , 2017, PloS one.

[36]  Guoping Cai,et al.  Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. , 2017, Cancer discovery.

[37]  Nir Hacohen,et al.  Resistance to checkpoint blockade therapy through inactivation of antigen presentation , 2017, Nature Communications.

[38]  Benjamin J. Strober,et al.  Merkel cell polyomavirus recruits MYCL to the EP400 complex to promote oncogenesis , 2017, PLoS pathogens.

[39]  Ann E. Sizemore,et al.  Computational correction of copy-number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells , 2017, Nature Genetics.

[40]  J. Becker,et al.  Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma , 2017, Scientific Reports.

[41]  Yun Yan,et al.  Loss of Polycomb Group Protein Pcgf1 Severely Compromises Proper Differentiation of Embryonic Stem Cells , 2017, Scientific Reports.

[42]  Oliver H. Chang,et al.  Polyomavirus-Negative Merkel Cell Carcinoma: A More Aggressive Subtype Based on Analysis of 282 Cases Using Multimodal Tumor Virus Detection. , 2017, The Journal of investigative dermatology.

[43]  Geet Duggal,et al.  Salmon: fast and bias-aware quantification of transcript expression using dual-phase inference , 2017, Nature Methods.

[44]  Rob Patro,et al.  Salmon provides fast and bias-aware quantification of transcript expression , 2017, Nature Methods.

[45]  Giovanni Martinelli,et al.  Optimized pipeline of MuTect and GATK tools to improve the detection of somatic single nucleotide polymorphisms in whole-exome sequencing data , 2016, BMC Bioinformatics.

[46]  T. Graeber,et al.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.

[47]  M. Shipp,et al.  NLRC5/MHC class I transactivator is a target for immune evasion in cancer , 2016, Proceedings of the National Academy of Sciences.

[48]  S. Haferkamp,et al.  RB1 is the crucial target of the Merkel cell polyomavirus Large T antigen in Merkel cell carcinoma cells , 2016, Oncotarget.

[49]  Donna Neuberg,et al.  The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. , 2016, Cancer cell.

[50]  H. Stunnenberg,et al.  Non-canonical PRC1.1 Targets Active Genes Independent of H3K27me3 and Is Essential for Leukemogenesis. , 2016, Cell reports.

[51]  T. Chan,et al.  Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy , 2015, Oncotarget.

[52]  Meagan E. Sullender,et al.  Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9 , 2015, Nature Biotechnology.

[53]  M. Robinson,et al.  Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences , 2015, F1000Research.

[54]  M. Robinson,et al.  Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. , 2015, F1000Research.

[55]  K. Cibulskis,et al.  Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes , 2015, Nature Biotechnology.

[56]  Guang Lan Zhang,et al.  Physical detection of influenza A epitopes identifies a stealth subset on human lung epithelium evading natural CD8 immunity , 2015, Proceedings of the National Academy of Sciences.

[57]  D. Reinberg,et al.  USP7 Cooperates with SCML2 To Regulate the Activity of PRC1 , 2015, Molecular and Cellular Biology.

[58]  D. Coit,et al.  Assessment of Cancer Cell Line Representativeness using Microarrays for Merkel Cell Carcinoma , 2014, The Journal of investigative dermatology.

[59]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[60]  B. van Steensel,et al.  Easy quantitative assessment of genome editing by sequence trace decomposition , 2014, Nucleic acids research.

[61]  Olga K Afanasiev,et al.  Downregulation of MHC-I Expression Is Prevalent but Reversible in Merkel Cell Carcinoma , 2014, Cancer Immunology Research.

[62]  E. Quintana,et al.  Merkel Cell Carcinoma Dependence on Bcl-2 Family Members for Survival , 2014, The Journal of investigative dermatology.

[63]  C. Fennelly,et al.  YY1 DNA binding and interaction with YAF2 is essential for Polycomb recruitment , 2013, Nucleic acids research.

[64]  P. Moore,et al.  Response of Merkel Cell Polyomavirus-Positive Merkel Cell Carcinoma Xenografts to a Survivin Inhibitor , 2013, PloS one.

[65]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[66]  Sean R. Davis,et al.  SRAdb: query and use public next-generation sequencing data from within R , 2013, BMC Bioinformatics.

[67]  S. Haferkamp,et al.  Merkel cell polyomavirus status is not associated with clinical course of Merkel cell carcinoma. , 2011, The Journal of investigative dermatology.

[68]  Thomas M Green,et al.  A public genome-scale lentiviral expression library of human ORFs , 2011, Nature Methods.

[69]  Yuan Chang,et al.  Merkel Cell Polyomavirus-Infected Merkel Cell Carcinoma Cells Require Expression of Viral T Antigens , 2010, Journal of Virology.

[70]  L. Chin,et al.  Array-CGH reveals recurrent genomic changes in Merkel cell carcinoma including amplification of L-Myc. , 2009, The Journal of investigative dermatology.

[71]  C. Sánchez,et al.  Proteomics Analysis of Ring1B/Rnf2 Interactors Identifies a Novel Complex with the Fbxl10/Jhdm1B Histone Demethylase and the Bcl6 Interacting Corepressor*S , 2007, Molecular & Cellular Proteomics.

[72]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[73]  S. Ferrone,et al.  Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions. , 2005, Advances in cancer research.

[74]  G. Yang,et al.  DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. , 2001, Carcinogenesis.

[75]  L. Kaer,et al.  Impaired assembly yet normal trafficking of MHC class I molecules in Tapasin mutant mice. , 2000, Immunity.

[76]  J. Girdlestone.  Regulation of HLA class I loci by interferons. , 1995, Immunobiology.

[77]  J. Kearsley,et al.  Characterization of cell lines established from merkel‐cell (“small‐cell”) carcinoma of the skin , 1993, International journal of cancer.

[78]  L. T. Peltenburg,et al.  Downregulation of HLA class I expression by c-myc in human melanoma is independent of enhancer A. , 1993, Nucleic acids research.

[79]  R. Weinberg,et al.  N-myc amplification causes down-modulation of MHC class I antigen expression in neuroblastoma , 1986, Cell.